Discover the Immunotherapy Funnel & PSI’s Contribution for Accelerating Discovery & Development.
Predict Response: Immunotherapy & Single-Cell Proteomics Evolving Together
In recent years, chemo- and radiotherapies have been supplanted by therapeutics aimed at turning one’s immune system against disease. Cancer immunotherapies, in particular immune checkpoint blockade and combination therapies, have demonstrated remarkable success in treating multiple refractory cancers.
Your Data is Secure
We will always keep your personal information safe and not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.
You may unsubscribe and update your email subscription at any time.
In this E-Book we discuss:
-
Addressing Challenges in Solid Tumors with IsoPlexis’ Single-Cell Proteomics and Polyfunctional Strength Index PSITM
-
Finding Critical, Correlative Differences using IsoPlexis’ Systems
-
Utilizing Polyfunction with Combination Immunotherapies to Stratify Patients: The Vision
Improving T Cell Function in the Solid Tumor Microenvironment with Combination Immunotherapeutic Strategies and Polyfunction PSI™
Discover the Immunotherapy Funnel & PSI's Contribution for Accelerating Discovery & Development. Predict Response: Immunotherapy & Single-Cell Proteomics Evolving Together In recent years, chemo- and radiotherapies have been supplanted by therapeutics aimed at turning one’s immune system against disease. Cancer immunotherapies, in particular immune checkpoint blockade and combination therapies, have demonstrated remarkable success in treating multiple refractory cancers.
